Evolv Technologies Holdings (Nasdaq: EVLV) sells AI-assisted walk-through weapons screening to schools, stadiums and hospitals on multi-year subscriptions. Stoic Point Capital Management (@stoic_point), a long-running Evolv bull, argued on October 12, 2026 that the company has "Fantastic economics that keep getting better," days after flagging what it called a systemwide hospital deal. With the stock at $4.53 on October 9, down from $7.31 in early January, the debate on X is whether Evolv's growth is arriving on profitable terms; the next checkpoint is its third-quarter report.
This is journalism and commentary, not investment advice. We hold no position unless stated.
Key facts
- Ticker and exchange: Evolv Technologies Holdings, Inc., EVLV, Nasdaq.
- Situation type: A contrarian growth call on a stock that has sold off despite raised guidance and a regulatory reset.
- The call: Stoic Point is long, arguing the unit economics are better than the market thinks.
- Price: EVLV closed at $4.53 on October 9, 2026, versus a $7.31 close on January 5, 2026.
- Latest quarter: Second-quarter 2026 revenue of $43.8 million, up 34%, with annual recurring revenue (ARR) of $132.7 million, up 20%.
- Profitability: A Q2 net loss of $9.3 million, but adjusted EBITDA of $4.4 million and a remaining performance obligation of $312.6 million.
- Guidance: 2026 revenue of $180 million to $185 million, raised from $175 million to $180 million, and adjusted EBITDA of $15 million to $16 million.
- Regulatory history: A November 2024 FTC order bars Evolv from unsupported claims about its screening.
Is EVLV a good bet right now?
The bull case is that a business with $312.6 million of contracted future revenue, rising ARR and positive adjusted EBITDA trades as if its model is broken. If renewals stay strong and new customers keep arriving, the market may be overweighting past controversies.
The bear case is that the company still loses money on a GAAP basis, its reputation took real damage from the FTC case, and the shift toward upfront hardware sales flatters near-term revenue. This is a debate about quality of growth, not a recommendation.
Why are bulls defending Evolv's economics?
- Contract structure. Stoic Point describes "4yr guaranteed deals, every year paid up front, cash flow generative, well over 100% NRR." Those are the account's characterizations; the company reports ARR and RPO but investors should check the filings for renewal data.
- New verticals. On October 8, Stoic Point posted that "$EVLV lands a big systemwide hospital deal across Kentucky and W. Virginia."
- Margins. Paris Analyst (@ParisAnalyst), a self-described New York portfolio manager, replied in the same debate, "Margins aren't an issue for them."
- Momentum in the numbers. Evolv added 70 new customers in the second quarter and raised its full-year Outlook, according to its second-quarter release.
Who's making this call and why?
Stoic Point Capital Management is a small-cap value and special-situations account that has posted about Evolv since at least December 2024. Its October 12 post framed the thesis around unit economics rather than headline growth.
Track record. In our tracking, Stoic Point is 5-4 (a .556 win rate) on 9 calls scored at 180 days against the S&P 500, with an average edge of +9.1 percentage points. That is fewer than 15 scored calls, so the account is not yet ranked; three newer calls are 2-1 on a provisional basis. See the Market Calls scoreboard.
Who disagrees?
Fierce_beast (@Fierce__beast), a self-described portfolio manager, put the bear point concisely in a reply: "adoption doesn't matter if it's arriving at bad economic terms." That is the crux. Evolv says about 60% of 2026 deployments will use its purchase subscription model, which pulls revenue forward and creates a modest headwind to reported gross margin because hardware costs are booked upfront.
Other concerns are on the record. The FTC action alleged Evolv deceived customers about its screening and let certain school customers cancel contracts signed between April 2022 and June 2023. The company has also been through an SEC investigation and a restatement, and the stock is down about 38% from its January close.
What are the key facts to verify?
- The second-quarter 2026 results, including ARR, RPO, cash of $63.4 million and the raised Outlook.
- Whether the hospital deal is Evolv's: Appalachian Regional Healthcare announced a systemwide screening rollout starting October 5, 2026, but the coverage we reviewed does not name a vendor.
- Net revenue retention and renewal data in future filings, since the over-100% figure is the bull's claim.
- The terms of the FTC order and how many customers used the cancellation option.
What would prove it right or wrong?
Right: Evolv hits or beats the $180 million to $185 million revenue range, ARR reaches the $148 million to $150 million target, adjusted EBITDA lands near $15 million to $16 million, and renewals stay strong.
Wrong: Guidance slips, GAAP losses widen, the hospital rollout turns out to use another vendor, or new regulatory problems hit sales.
This is journalism and commentary, not investment advice. We hold no position unless stated.